Neuro-Oncology Reviews

Volume 28 Number 1
10 January 2026

Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 1, 10 January

Vrachas D, Kosma E, Giannopoulou AI, Margoni A, Gargalionis AN, El-Habr EA, Piperi C, Adamopoulos C.
Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities.
Cancers (Basel). 2026 Jan 2;18(1):156. doi: 10.3390/cancers18010156. PMID: 41514664. Review. ˍ

Gómez EG, Morales MAM, San-Juan D, Romero-Valencia J, Mendez DLR, Hernandez DOL, Pizarro MM, Narvaez ERB, Pelayo-Salazar ME, Jimenez SM.
Efficacy and safety of immune checkpoint inhibitors and mTOR inhibitors as targeted therapy for glioblastoma: A systematic review and meta-analysis of randomized clinical trials.
Neurosurg Rev. 2026 Jan 3;49(1):95. doi: 10.1007/s10143-025-04043-6. PMID: 41484472. Review; Meta-analysis˰ ˍ

Sanikommu S, Santos AN, Wipplinger C, Dawoud B, Komotar RJ, Lu VM.
Patient-reported outcomes as prognostic indicators for overall survival and progression-free survival in brain tumor patients - a systematic review and meta-analysis of randomized clinical trials.
J Neurooncol. 2026 Jan 5;176(2):154. doi: 10.1007/s11060-025-05419-w. PMID: 41491296. Review; Meta-analysis. ˍ

Khafaga DSR, Basem Y, AlAtar HM, Sherif A, Ata A, Sabry F, El-Morsy MT, Attia SS.
Cancer Neuroscience: Linking Neuronal Plasticity with Brain Tumor Growth and Resistance.
Biology (Basel). 2026 Jan 6;15(2):108. doi: 10.3390/biology15020108. PMID: 41594844. Review. ˍ

Rahman MA, Yadab MK, Ali MM.
Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug Delivery.
Nutrients. 2026 Jan 7;18(2):194. doi: 10.3390/nu18020194. PMID: 41599806. Review. ˍ

Fan L, Wu H, Zhang Y, Yu B, Feng J, Du Y, Yan X, Che L, Xu S, Li Y.
The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis.
Neuroscience. 2026 Jan 8;596:36-44. doi: 10.1016/j.neuroscience.2025.12.064. PMID: 41519428. Review; Meta-analysis˰ ˍ

Goh LSH, Thng DKH, Ang YLE, Ho D, Toh TB, Wong ALA.
The functional imperative in high-grade glioma.
Exp Mol Med. 2026 Jan 8. doi: 10.1038/s12276-025-01614-x. PMID: 41501375. Review. ˍ

Li X, Liu Z, Liu K, Wang C, Liu Z, Xu X.
Advances in Clinical Trials of Boron Neutron Capture Therapy.
Research (Wash D C). 2026 Jan 8;9:0988. doi: 10.34133/research.0988. PMID: 41522606. Review. ˍ

Moreno-Sanchez PM, Rezaeipour M, Inderberg EM, Platten M, Golebiewska A.
Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.
Nat Cancer. 2026 Jan 8. doi: 10.1038/s43018-025-01097-9. PMID: 41507535. Review˰ ˍ

Harper SD, Alderete JA, Baisiwala S, Bergsneider BH, Liau LM, Wang AC.
Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.
J Neurooncol. 2026 Jan 8;176(2):158. doi: 10.1007/s11060-025-05403-4. PMID: 41504830. Review. ˍ

Agarwal S, Han S, Lal A, Vira V, Chandla A, Mehranpour P, Yang I, Wadehra M.
A Comprehensive Review of Immunotherapeutic Modalities in Glioblastoma: Mechanisms, Efficacy, and Safety Considerations.
Cancers (Basel). 2026 Jan 9;18(2):212. doi: 10.3390/cancers18020212. PMID: 41595133. Review. ˍ

Fortunato JT, Scharf A, Shuman AG, Diamond EL.
Staging prognostic discussions about glioblastoma.
J Neurooncol. 2026 Jan 9;176(2):162. doi: 10.1007/s11060-025-05356-8. PMID: 41511573. Review. ˍ